Leitlinie der Pädiatrische Arbeitsgemeinschaft AIDS (PAAD) e.V. zur antiretroviralen Therapie bei HIV-infizierten Kindern und Jugendlichen (2011)

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Klinische Pädiatrie

• Publication date

  2012-03-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/s-0031-1301309PMID 22407471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tipranavir

  2012cited by this paper
• Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents

  2011cited by this paper
• Induction maintenance concept for HAART as initial treatment in HIV infected infants

  2011cited by this paper
• Decreased Apoptosis Despite Severe CD4 Depletion in the Thymus of a Human Immunodeficiency Virus-1 Infected Child

  2011cited by this paper
• First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

  2011cited by this paper
• HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine

  2011cited by this paper
• Terminally Differentiated CD8 Cells in HIV-Infected Children: HIV-GAG/POL Specificity and IFN-γ Production

  2011cited by this paper
• Pharmacokinetic Optimization of Antiretroviral Therapy in Children and Adolescents

  2011cited by this paper
• HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.

  2011cited by this paper
• Risk of triple-class virological failure in children with HIV: a retrospective cohort study

  2011cited by this paper
• Tenofovir Disoproxil Fumarate and Bone Mineral Density: A 60-Month Longitudinal Study in a Cohort of H V -Infected Youths

  2010cited by this paper
• Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial

  2010cited by this paper
• Pandemic influenza A (H1N1) outbreak among 15 school-aged HIV-1-infected children.

  2010cited by this paper
• Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.

  2010cited by this paper
• Antiretroviral therapy and bone mineral measurements in HIV-infected youths.

  2010cited by this paper
• Antiretroviral treatment for children with peripartum nevirapine exposure.

  2010cited by this paper
• Darunavir

  2010cited by this paper
• HOSPITALIZATIONS FOR INVASIVE PNEUMOCOCCAL DISEASE AMONG HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTED CHILDREN, ADOLESCENTS AND YOUNG ADULTS IN THE UNITED STATES IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND THE CONJUGATE PNEUMOCOCCAL VACCINE

  2010cited by this paper
• Pediatric aspects of HIV1-infection--an overview.

  2010cited by this paper
• Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

  2010cited by this paper
• Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection

  2009cited by this paper
• Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

  2009cited by this paper
• Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

  2009cited by this paper
• Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants

  2009cited by this paper
• Therapeutic drug monitoring of antiretrovirals for people with HIV.

  2009cited by this paper
• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  2009cited by this paper
• The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time

  2009cited by this paper
• Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

  2009cited by this paper
• The fusion inhibitor enfuvirtide in recent antiretroviral strategies

  2009cited by this paper
• Management of paediatric HIV-1 resistance

  2009cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• A Systematic Review of Pediatric Adherence to Antiretroviral Therapy in Low- and Middle-Income Countries

  2008cited by this paper
• Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.

  2008cited by this paper
• Lipid Screening and Cardiovascular Health in Childhood

  2008cited by this paper
• Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.

  2008cited by this paper
• Current and Future Antiretroviral Treatment Options in Paediatric HIV Infection

  2008cited by this paper
• Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents

  2008cited by this paper
• Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.

  2008cited by this paper
• Early antiretroviral therapy and mortality among HIV-infected infants.

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

  2008cited by this paper
• Assessment of Adherence to Antiretroviral Therapy in Perinatally HIV-Infected Children and Youth Using Self-Report Measures and Pill Count

  2008cited by this paper
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

  2008cited by this paper
• In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children

  2007cited by this paper
• Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

  2007cited by this paper
• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

  2007cited by this paper
• Adherence to Antiretroviral Therapy for Pediatric HIV Infection: A Qualitative Systematic Review With Recommendations for Research and Clinical Management

  2007cited by this paper
• Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.

  2007cited by this paper
• Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children

  2006cited by this paper
• Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children

  2006cited by this paper
• Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children

  2006cited by this paper
• A Randomized Controlled Trial of Genotypic HIV Drug Resistance Testing in HIV-1-Infected Children: The Pera (Penta 8) Trial

  2006cited by this paper
• Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study

  2006cited by this paper
• Different Kinetics of Immunologic Recovery Using Nelfinavir or Lopinavir/Ritonavir-Based Regimens in Children with Perinatal HIV-1 Infection

  2005cited by this paper
• Prevalence of Elevated Cholesterol and Associated Risk Factors Among Perinatally HIV-Infected Children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C

  2005cited by this paper
• Nucleoside Analogues Toxicities Related to Mitochondrial Dysfunction: Focus on HIV-Infected Children

  2005cited by this paper
• Plasma Pharmacokinetics of Once- versus Twice-Daily Lamivudine and Abacavir: Simplification of Combination Treatment in HIV-1-Infected Children (Penta-13)

  2005cited by this paper
• Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine

  2005cited by this paper
• Tipranavir: A Ritonavir-Boosted Protease Inhibitor

  2005cited by this paper
• Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.

  2005cited by this paper
• Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

  2004cited by this paper
• A trial of three antiretroviral regimens in HIV-1-infected children.

  2004cited by this paper
• Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children

  2004cited by this paper
• Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects

  2004cited by this paper
• Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome

  2004cited by this paper
• Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.

  2004cited by this paper
• Hyperlactatemia in Human Immunodeficiency Virus–Uninfected Infants Who Are Exposed to Antiretrovirals

  2004cited by this paper
• Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.

  2004cited by this paper
• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

  2004cited by this paper
• Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis.

  2003cited by this paper
• Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

  2003cited by this paper
• Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study

  2003cited by this paper
• Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

  2003cited by this paper
• Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

  2003cited by this paper
• Latency in Human Immunodeficiency Virus Type 1 Infection: No Easy Answers

  2003cited by this paper
• Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

  2003cited by this paper
• Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment

  2003cited by this paper
• Nevirapine use in HIV-1-infected children

  2003cited by this paper
• Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

  2003cited by this paper
• Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort

  2003cited by this paper
• Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

  2002cited by this paper
• Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

  2002cited by this paper
• Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

  2002cited by this paper
• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  2002cited by this paper
• A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

  2002cited by this paper
• Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.

  2002cited by this paper
• Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

  2002cited by this paper
• Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

  2002cited by this paper
• Virulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse Transcriptase

  2002cited by this paper
• Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)

  2002cited by this paper
• Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088)

  2002cited by this paper
• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  2002cited by this paper
• Hyperlipidemia in HIV‐Infected Children Treated With Protease Inhibitors: Relevance for Cardiovascular Diseases

  2002cited by this paper
• Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy.

  2001cited by this paper
• Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten KindernVollständig überarbeitetes und aktualisiertes Konsensusstatement der Pädiatrischen Arbeitsgemeinschaft Aids (PAAD) und der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI)

  2001cited by this paper
• Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern

  2001cited by this paper
• Tolerance of efavirenz in children

  2001cited by this paper
• Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

  2000cited by this paper
• Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

  2000cited by this paper
• Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

  2000cited by this paper
• Predictive value of the HIV paediatric classification system for the long-term course of perinatally infected children.

  2000cited by this paper

• HIV-Infektion und AIDS

  2020cites this paper
• HIV-Infektion und AIDS bei Kindern und Jugendlichen

  2020cites this paper
• Antivirale Therapie

  2019cites this paper
• Health Workers’ Perspectives on the Outcomes, Enablers, and Barriers to the Implementation of HIV “Test and Treat” Guidelines in Abuja, Nigeria

  2019cites this paper
• Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhood

  2017cites this paper
• HIV-1 Subtype Diversity and Prevalence of Primary Drug Resistance in a Single-Center Pediatric Cohort in Germany

  2017cites this paper
• Sexuell übertragbare Infektionen und prophylaktische Maßnahmen

  2016cites this paper
• Future Developments of Clinical Research in Pediatrics: The Role of the Journal Klinische Pädiatrie

  2013cites this paper
• HIV und Immundefizienzsyndrom (AIDS)

  2013cites this paper